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ponent summary score as well as on the general health,
vitality, social functioning and role emotional domains of
the SF-36 (P  0.05). CONCLUSIONS: The results of
this interim analysis suggest that TM patients have a
lower quality of life than patients with EM.
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Patients who received at least one abortive migraine pre-
scription during July 1998 through December 1998 and
who had been continuously enrolled in a large west coast
health maintenance organization (HMO) for that period
were identified through the HMO pharmacy prescription
database and screened for eligibility criteria. Eligible
HMO patients were those who did not have any sensitiv-
ity nor contraindications to receiving Excedrin-migraine.
Patients from four medical groups in Southern California
were asked to participate based on the groups’ higher
than network migraine prescription utilization. Physician
groups who participated in the program consisted mainly
of primary care physicians or family practitioners and a
small proportion of neurologists. OBJECTIVE: To evalu-
ate the effects of an over-the-counter (OTC) migraine
medication on patient quality-of-life two and four months
after initiation therapy. METHODS: This was an obser-
vational study where enrolled patients received a one
month supply of Excedrin-migraine samples along with a
self-administered SF-36 questionnaire to complete at
baseline, months two and four. All data were analyzed
using SAS statistical software (version 6.12) with  set at
0.05. RESULTS: Results at month four indicated im-
provements in both MCS (P  0.05) and PCS scores. In
addition, there were improvements in seven of the eight
domains of the SF-36 with Role Physical, Bodily Pain, Vi-
tality and Social Functioning being significantly different
(P  0.05). CONCLUSION: In the four months after ini-
tiation of the OTC migraine program, quality-of-life
scores improved for the migraineurs enrolled in the
study.
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MODELING LENGTH OF PRESCRIPTION 
THERAPY FOR DEPRESSION PATIENTS
Billingsley J-K, Nichols JL
IMS Health, Plymouth Meeting, PA, USA
Length of therapy can affect clinical outcomes as well as
total healthcare costs that patients incur. Understanding
which factors influence length of therapy can be a major
step in managing treatment. OBJECTIVE: To identify
factors affecting length of antidepressant pharmacother-
apy for depression patients. METHODS: Using an em-
ployer claims database, antidepressant prescription claims
of 2,830 depression patients were analyzed for 18
months following their initial prescription for a SSRI/
SNRI, Newer Generation Antidepressant, or Tricyclic/
Tetracyclic in 1996. A wide range of demographic, pa-
tient- and prescription-level data were reviewed. Linear
regression modeling was implemented to model length of
antidepressant pharmacotherapy as a function of explan-
atory variables. RESULTS: The linear regression model
estimated length of prescription therapy as f (age, physi-
cian specialty prescribing medication, number of unique
drugs prescribed, starting drug therapy class, switch in
drug therapy class [yes/no], and number of gaps in ther-
apy). The model was significant (P  0.05) overall, as
was each regressor. Based on findings, the following in-
ferences can be made: (1) older patients underwent
longer therapy; (2) patients treated by a psychologist/
neurologist or both a primary care physician and a psy-
chologist/neurologist underwent longer therapy than pa-
tients treated by primary care physicians exclusively; pa-
tients treated by other physician specialties underwent
shorter therapy; (3) each additional, unique drug pre-
scribed resulted in longer total therapy; (4) patients ini-
tially treated with SSRIs/SNRIs had longer therapy than
patients initially treated with other antidepressant cate-
gories; and (5) each additional gap in therapy resulted in
progressively longer therapy. CONCLUSION: A positive
relationship was observed between the length of patient’s
antidepressant pharmacotherapy and a number of fac-
tors. A thorough understanding and management of
these factors could lead to improved patient outcomes.
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OBJECTIVE: To assess the treatment of childhood de-
pression in a managed care population. METHODS: All
subjects contained within Pharmetric’s Integrated Out-
comes database possessing a diagnosis of depression
(ICD-9-CM  296.2, 296.3, 300.4, 311) during 1997–98,
who were between 6–18 years of age at the time of diag-
nosis and were continuously enrolled for more than 1
year, were eligible for study inclusion. Utilization of psy-
chotherapy and pharmacotherapy during the 1-year pe-
riod following initial diagnosis was measured, as was de-
pression-related hospitalization. These measures were
compared across age categories (6–14, 15–18) and gen-
der, and hospitalization rates were compared across psy-
chotherapy and pharmacotherapy cohorts. RESULTS:
461 patients met the inclusion criteria. The mean age was
15.4 years and 51.4% of the sample was female. 96.5%
of patients received some type of pharmacotherapy,
while only 214 (46.4%) subjects received psychotherapy.
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While patients in the younger group were more likely to
be male (69.3%), the majority of patients in 15–18 age
category were female (59.3%). Older patients were less
likely to receive psychotherapy treatment (P  0.01).
During the year, 99 (21.5%) patients were hospitalized
for depression. Females were more likely to receive more
than one class of antidepressant (24.1% vs. 13.39%).
The difference was more pronounced within the 15–18
age category (26.3% vs. 11.0%). Hospitalization rates
were higher among older patients (25.2%) compared to
younger patients (11.8%). Hospitalization was not re-
lated to the presence of psychotherapy, but it was associ-
ated with the multiple antidepressant treatment (P 
0.01). CONCLUSION: Hospitalization was a common
outcome for patients, suggesting the need for improved
treatment.
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Drug-drug interactions are well documented and are
known to change pharmacokinetic properties of an
agent, affecting efficacy and increasing the risk for side
effects or adverse events. While clinical trial and labora-
tory data assess the mechanism of these interactions, a
compelling part of the picture is missing, the clinical and
economic consequences associated with these events. OB-
JECTIVES: The purpose of this analysis was to identify
changes in incurred charges related to the treatment of
depression with respect to the concurrent use of drugs
with interaction potential. METHODS: Complete medi-
cal and pharmacy claim records were collected for pa-
tients with depression by using an episoding methodol-
ogy. Data collection began with the episode start and
continued for 1 year. For patients with the use of specific
antidepressants, cohorts were formed using the presence
of concurrent use with other prescription drugs having
documented interaction potential. Total depression
related expenditures for patients with concurrent drug
use were collected and compared to a matched patient
group. RESULTS: A total of 4,655 patients were selected
for observation, 1,681 had evidence of at least one (1) in-
stance of co-administration of interacting agents. Of all
patients, fluoxetine users had the greatest percentage of
co-administration (39.9%) and bupropion users had
the least amount (7.9%). When observing incurred
healthcare charges, the average total yearly charges for
treating depression were 35% higher for patients with
the presence of drug co-administration than compared
to matched patient group ($2,513 vs. $1,860, respec-
tively, P  0.001). Service categories that were major
drivers included professional visits, testing, outpatient fa-
cility, and prescription drugs. CONCLUSIONS: The
presence of antidepressant drug co-administration seems
to correlate with increased charges specific to the treat-
ment of depression. This information is a compelling in-
dicator that drug interactions are clinically significant
and have serious economic consequences. Careful selec-
tion of antidepressants can avoid additional resource uti-
lization.
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With the introduction of atypical neuroleptic medications
into the market place, usage of conventional neuroleptics
has fallen with the perception of a more favorable atypi-
cal side effect profile. Although there is some evidence
that atypical neuroleptics are associated with a decreased
occurrence of tardive dyskinesia (TD), reports of atypi-
cal-induced TD are appearing in the literature. OBJEC-
TIVE: The purpose of this study was to determine the
risk of TD associated with atypical and conventional
neuroleptics. METHODS: Subjects were adult users of
the Veterans Administration Puget Sound Health Care
System who received 1 prescriptions for neuroleptic
medications during the study period. Electronic medical
and pharmacy records were used to obtain neuroleptic
drug exposure, exclusionary diagnosis, diagnosis for TD,
and select demographic data. Medical records were re-
viewed to collect demographic data not available elec-
tronically. The case-defining event was the diagnosis of
TD. Controls were randomly selected from a cohort of
neuroleptic users without TD. RESULTS: There were 48
cases and 179 controls for the final analysis. The only de-
mographic difference found was a higher proportion of
cases (92%) than controls (76%) were Caucasian. Con-
ventional neuroleptic users had an insignificant increase
in risk of TD over atypical neuroleptic users (OR  1.16;
95%CI  0.607–2.21). After adjusting for age, gender,
race, schizophrenia, schizo-affective disorder, depression,
and antiparkinson drugs, there was still no significant
difference in risk of TD between cases and controls (OR 
1.46; 95% CI  0.625–3.414). CONCLUSIONS: These
results suggest users of conventional neuroleptics may be
at increased risk of TD compared to users of atypical
neuroleptics, however in this population the increase was
not significant.
